Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of Repatha in homozygous familial hypercholesterolemia patients in India
2020-005111-51Phase 4
- Sponsor
- Amgen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Amgen. Primary endpoint: Treatment-emergent adverse events incidence.
02
Drugs
evolocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2020-005111-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005111-51.